Sylwer fod y cymhwysiad hwn dan ddatblygiad. Os ydych chi'n gweld unrhyw gamgymeriadau neu os nad yw rhywbeth yn gweithio, cysylltwch â ni yn evidence.service@wales.nhs.uk.

Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation

Hartmann-Boyce J et al (2019)

Cochrane Database of Systematic Reviews - DOI: 10.1002/14651858.CD009670.pub4.

Mapiau Tystiolaeth

  • Lleoliadau Gofal: Lleoliad gofal iechyd
  • Grwpiau Poblogaeth: Milwrol / cyn-filwrol
  • Grwpiau Poblogaeth: Oedolion
  • Grwpiau Poblogaeth: Chyflyrau iechyd sy'n bodoli eisoes
  • Grwpiau Poblogaeth: Hanes blaenorol o gamddefnyddio sylweddau
  • Ymyriadau: Bupropian
  • Ymyriadau: Aml-gydran
  • Ymyriadau: Therapi Ymddygiad Gwybyddol
  • Ymyriadau: Cyfweld ysgogiadol
  • Ymyriadau: Cymorth Ymddygiad
  • Ymyriadau: Ffarmacotherapïau eraill
  • Ymyriadau: Therapi Amnewid Nicotin
  • Ymyriadau: Varenicline
  • Canlyniad: Rhoi'r gorau i ysmygu
  • Canlyniad: Newidiadau i gyfraddau ysmygu

Math o Dystiolaeth

Adolygiad Systematig

Nodau

Mae'r awduron yn datgan:

"To evaluate the effect of adding or increasing the intensity of behavioural support for people using smoking cessation medications, andto assess whether there are different effects depending on the type of pharmacotherapy, or the amount of support in each condition."

Canfyddiadau

Mae'r awduron yn datgan:

"Eighty-three studies, 36 of which were new to this update, met the inclusion criteria, representing 29,536 participants. Overall, we judged 16 studies to be at low risk of bias and 21 studies to be at high risk of bias. All other studies were judged to be at unclear risk of bias. Results were not sensitive to the exclusion of studies at high risk of bias. We pooled all studies comparing more versus less support in the main analysis. Findings demonstrated a benefit of behavioural support in addition to pharmacotherapy. When all studies of additional behavioural therapy were pooled, there was evidence of a statistically significant benefit from additional support (RR 1.15, 95% CI 1.08 to1.22, IM = 8%, 65 studies, n = 23,331) for abstinence at longest follow-up, and this effect was not different when we compared subgroups by type of pharmacotherapy or intensity of contact. This effect was similar in the subgroup of eight studies in which the control group received no behavioural support (RR 1.20, 95% CI 1.02 to 1.43, IM = 20%, n = 4,018). Seventeen studies compared interventions matched for contact time but that differed in terms of the behavioural components or approaches employed. Of the 15 comparisons, all had small numbers of participants and events. Only one detected a statistically significant effect, favouring a health education approach (which the authors described as standard counselling containing information and advice) over motivational interviewing approach (RR 0.56, 95% CI0.33 to 0.94, n = 378)."

Casgliadau

Mae'r awduron yn datgan:

"There is high-certainty evidence that providing behavioural support in person or via telephone for people using pharmacotherapy to stop smoking increases quit rates. Increasing the amount of behavioural support is likely to increase the chance of success by about 10% to 20%, based on a pooled estimate from 65 trials. Subgroup analysis suggests that the incremental benefit from more support is similar over a range of levels of baseline support. More research is needed to assess the effectiveness of specific components that comprise behavioural support."